Remove 2030 Remove Disease Remove Therapies
article thumbnail

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

The Pharma Data

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). trillion per year by 2030.

article thumbnail

Lilly’s donanemab receives U.S. FDA’s Breakthrough Therapy designation for treatment of Alzheimer’s disease

The Pharma Data

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

The Pharma Data

Alzheimer’s is the most common form of madness, which presently affects farther than 55 million people worldwide, and is projected to reach 78 million by 2030. trillion per space by 2030. Much 10 million people widely are diagnosed with Notice each space.

Disease 52
article thumbnail

Investment Trends in Pharmaceutical Research

DrugBank

Humira , AbbVie's monoclonal antibody for autoimmune diseases, generated over $20 billion in annual revenue at its peak before losing patent exclusivity in 2023.  This exponential growth is primarily fueled by the escalating global burden of chronic diseases. billion by 2030. trillion by 2028.

article thumbnail

Development of Blood-Based Alzheimer’s Prognostic Propels Diadem to Finalist Status for Both the Gaetano Marzotto Company Prize and 2030 Social Impact Special Prize

The Pharma Data

Diadem’s Minimally Invasive Blood-Based AlzoSure® Prognostic Test for Early Alzheimer’s Disease Selected for Potential to Help Transform Management of this Devastating Global Disorder. “Alzheimer’s disease and other dementias afflict more than 50 million people worldwide. . MILAN , Nov.

Disease 40
article thumbnail

International Conference on Alzheimer’s & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer’s Disease Research

The Pharma Data

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40
article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease). Join the club.